InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,843.31
(
0.48%
)
US TECH 100
19,654.80
(
0.11%
)
Dow Jones
43,076.18
(
0.79%
)
Brent Oil
74.00
(
-0.64%
)
Bitcoin
67,877.61
(
1.30%
)
Post# of 19309
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 840
Posts 120576
Boards Moderated 14
Alias Born 09/05/2002

DewDiligence

Member Level

Re: keitern post# 11957

Monday, 06/23/2008 10:11:38 AM

Monday, June 23, 2008 10:11:38 AM

Post# of 19309
>I note the funding of clinical expenses vis. AD ind and bearing of all sales and marketing expense as well as the royalties that I assume are above and beyond the OA scope of this deal.<

That’s correct—the $257M figure does not include Ovation’s development expenses, payments to GTC for manufactured product, or royalties on commercial sales.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up